Russell Investments Group, Ltd. Chinook Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$18.66 - $38.58 $290,554 - $600,729	-15,571 Reduced 83.3%	3,121 $119,000
Q1 2023 May 09, 2023	BUY	$21.53 - $26.8 $71,070 - $88,466	3,301 Added 21.45%	18,692 $432,000
Q1 2022 May 05, 2022	SELL	$12.02 - $16.69 $29,545 - $41,024	-2,458 Reduced 13.77%	15,391 $251,000
Q4 2021 Jan 21, 2022	BUY	$10.69 - $16.83 $26,276 - $41,368	2,458 Added 15.97%	17,849 $291,000
Q1 2021 May 10, 2021	BUY	$14.17 - $19.11 $218,090 - $294,122	15,391 New	15,391 $239,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.